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Background: Lactobacillus gasseri SBT2055 (LG2055) has been shown to prevent abdominal adiposity, and
suppression of lipid absorption is considered a possible mechanism, detail of which, however, are poorly
understood. In the present study, we evaluated the effects of LG2055 on fat hydrolysis by determining pancreatic
lipase activity and fat emulsion properties in vitro. We also examined whether LG2055 influences fecal fat excretion
in humans.
Methods: Pancreatic lipase activity was investigated in vitro using an artificially prepared fat emulsion and
4-methylumbelliferyl oleate (4-MUO) as substrates. The concentrations of free fatty acids and 4-methylumbelliferone
were quantified. Fat emulsion droplet size was measured using a particle size analyzer. The clinical study was
performed as a double-blind, randomized, placebo-controlled trial. Subjects consumed 100 g of fermented milk
(FM)/d, either with or without LG2055 supplementation, for seven days. Fecal samples were collected during
three-day pre-observational and FM intake periods and fecal fat levels were determined.
Results: LG2055 dose-dependently suppressed lipase activity in the fat emulsion assay but not in the 4-MUO assay.
LG2055 dose-dependently increased fat emulsion droplet size. The effects of LG2055 on lipase activity and fat emulsion
properties were increased compared with four other tested strains (Lactobacillus gasseri SBT0317, Lactobacillus gasseri
JCM1131T, Lactobacillus. delbrueckii subsp. bulgaricus JCM1002T and Streptococcus thermophilus ATCC19258T). In
our clinical study, fecal fat level after FM intake was significantly increased compared with that observed before
FM intake in the LG2055-containing active FM group but not the control FM group lacking LG2055.
Conclusions: LG2055 increased fat emulsion droplet size, resulting in the suppression of lipase-mediated fat
hydrolysis. The influence of LG2055 on the physicochemical properties of fat emulsion provides a mechanism for
the probiotic-mediated suppression of lipid absorption and promotion of fecal fat excretion in humans.
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Lactobacillus gasseri SBT2055 (LG2055), a probiotic lactic
acid bacterium originating in the human intestine [1,2],
has an ability to improve the intestinal environment [3]
and exerts anti-obesity effects in rats [4-6] and mice [7].
Our previous clinical studies in Japanese adults with over-
weight exhibited a significantly decreased visceral fat area,
body weight, body mass index (BMI), and waist and hip
circumferences following consumption of fermented milk
containing LG2055 at 200 g/d for 12 weeks [8,9].
Suppression of lipid absorption in the small intestine
has been proposed as a potential mechanism for the
anti-obesity effects of LG2055. Hamad et al. evaluated
lymphatic lipid content in rats with permanent cannula-
tion of the thoracic duct [4]. They demonstrated that
rats fed a diet containing fermented skim milk supple-
mented with LG2055 showed a lower maximal rate of
lymphatic lipid absorption compared with rats fed a diet
containing non-fermented skim milk; these findings
were supported by the observation of increased fecal
fatty acid excretion [4]. Furthermore, our recent study
showed that Japanese hypertriacylglycerolemic subjects
who consumed fermented milk containing LG2055 at
200 g/d for 4 weeks demonstrated significantly de-
creased postprandial serum lipid concentrations after
the intake of oral fat-loading test meals [10]. Serum lipid
concentrations are influenced by not only lipid absorp-
tion via diet but also lipid metabolism. Therefore, esti-
mation of fecal lipid excretion is a more direct index to
examine dietary lipid absorption.
Dietary lipid digestion undergoes several complex
processes prior to mucosal absorption in the small intes-
tine. Pancreatic lipase is a key enzyme for lipid absorption
because the majority of lipolysis is carried out in the duo-
denum by pancreatic lipase that is secreted from the pan-
creas and hydrolyzes dietary lipid-derived triacylglycerol
into glycerol and fatty acids [11]. Dietary triacylglycerol,
the major source of dietary fat, is not directly absorbed in
the intestine unless it has been hydrolyzed by pancreatic
lipase. Therefore, suppression of lipase-mediated fat hy-
drolysis is an effective approach for suppression of dietary
triacylglycerol absorption [12].
Suppression of lipase-mediated fat hydrolysis is mainly
associated with two mechanisms: the first is direct enzym-
atic inhibition by an inhibitor like orlistat, which is a po-
tent pancreatic lipase inhibitor used as a pharmaceutical
agent for the management of obesity [13]; the second is
associated with modification of fat emulsion properties.
Fat emulsion interface properties, including droplet size
and specific surface area, influence the effects of lipase-
mediated fat hydrolysis on dietary fat absorption [14]. As
fat emulsion particle diameter increases, specific surface
area decreases. Thus, lipase-mediated fat hydrolysis is sen-
sitive to fat emulsion size [15], and the change in fatemulsion droplet size is critical for modification of fat di-
gestion and absorption. However, the mechanism of
LG2055-mediated suppression of lipid absorption is
unclear.
In this study, we investigated the mechanism associated
with suppression of lipid absorption by the probiotic
bacterium LG2055. We determined LG2055 effects on
pancreatic lipase-mediated hydrolysis of an artificial fat
emulsion or synthetic substrate (lipase activity) and
measured fat emulsion droplet size in vitro using a sim-
ple oil-in-water emulsion as a physiological model. We
also examined whether intake of LG2055 altered fecal




Triolein, taurocholic acid, pancreatic lipase (type VI-S,
from porcine pancreas), orlistat, and 4-methylumbelliferyl
oleate (4-MUO) were purchased from Sigma-Aldrich Co.,
Ltd. (St. Louis, MO, USA). N-Tris (hydroxymethyl)
methyl-2-aminoethanesulfonic acid (TES) was purchased
from Dojindo Laboratories (Kumamoto, Japan). Lecithin
from egg, NEFA C Test Wako, and catechin mixture from
green tea (product number 032–18231) were purchased
from Wako Pure Chemical Industries Co., Ltd. (Osaka,
Japan).
Preparation of LG2055 and other bacteria
Lactobacillus gasseri SBT2055 (LG2055), a bacterial
strain derived from a fecal specimen of a healthy adult
originally isolated by Fujiwara et al. [3] was deposited in
the International Patent Organism Depositary, National
Institute of Advanced Industrial Science and Technology
(Tsukuba, Ibaraki 305–8566, Japan). Lactobacillus gasseri
SBT0317 (LG0317) was isolated from a dairy product
and stocked at Megmilk Snow Brand Co. Ltd. [16].
Lactobacillus gasseri JCM1131T (LG1131T) and Lacto-
bacillus delbrueckii subspecies (subsp.) bulgaricus
JCM1002T (LB1002T) were obtained from the Japan
Collection of Microorganisms. Streptococcus thermophi-
lus ATCC19258T (ST19258T) was obtained from the
American Type Culture Collection (Manassas, VA,
USA). Each strain was grown at 37°C for 16 h in de
Man, Rogosa and Sharpe (MRS) broth (Becton-Dickinson
and Company, MD, USA). Harvested cells of each strain
were washed twice with saline and once with sterilized
water, then lyophilized using a freeze dryer (FDU-2200,
Tokyo Rikakikai Co., Ltd., Tokyo, Japan).
Measurement of pancreatic lipase activity
Pancreatic lipase activity using fat emulsion as a sub-
strate was determined using the method described by
Han et al. [17]. A fat emulsion was prepared by
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(80 mg), lecithin (10 mg), and taurocholic acid (5 mg) in
9 ml of TES buffer (0.1 M TES, 0.1 M NaCl, pH 7.0) for
25 min. Bacterial cells of each strain were suspended in
TES buffer. For the enzyme reaction, 100 μl of a bacterial
cell suspension or orlistat solution and 50 μl of pancreatic
lipase (10 units) were added to 100 μl of sonicated sub-
strate suspension (fat emulsion) in a total volume of
250 μl, and the reaction mixture was incubated at 37°C for
30 min. After completion of the reaction, the solution was
heated in a boiling water bath for 2 min for enzyme inacti-
vation. The blank of each sample was heated in a boiling
water bath for 2 min immediately following addition of
the enzyme solution for inactivation. The concentration of
released fatty acids was measured using a NEFA C Test
Wako. To examine dose-dependency, LG2055 suspen-
sions were prepared at final concentrations ranging from
1–100 μg/ml. The effects of five bacterial strains (LG2055,
LG1131T, LG0317, LB1002T and ST19258T) were com-
pared using preparations at final concentrations of
100 μg/ml. Pancreatic lipase activity of each sample was
calculated using fatty acid production in the absence of
sample as 100%. Lipase activity using 4-MUO as a sub-
strate [18] was determined using the method described by
Nakai et al. [19]. LG2055 cells were suspended in distilled
water. Twenty-five microliters of a LG2055 suspension or
an orlistat solution and 50 μl of a 0.1 mM 4-MUO so-
lution dissolved in Tris buffer consisting of 13 mM
Tris–HCl, 150 mM NaCl, and 1.3 mM CaCl2 (pH 8.0)
were mixed in the well of a microtiter plate, and 25 μl
of the lipase solution (50 U/ml) in Tris buffer was then
added to initiate the enzyme reaction. After incubation
at 25°C for 30 min, 100 μl of 0.1 M sodium citrate
(pH 4.2) was added to terminate the reaction. The
amount of 4-methylumbelliferone released following
the lipase reaction was measured using a fluorometrical
microplate reader (Varioskan™ Flash, Thermo Fisher
Scientific, Inc., MA, USA) at an excitation wavelength
of 327 nm and an emission wavelength of 449 nm. The
LG2055 suspensions and orlistat solutions were pre-
pared at final concentrations ranging from 1–100 μg/
ml, and 0.1–100 μg/ml, respectively. Pancreatic lipase
activity of each sample was calculated using 4-
methylumbelliferone production in the absence of sample
as 100%.
Measurement of particle size of fat emulsion
LG2055 was suspended in 1.2 ml of TES buffer and
added to 8 ml of the fat emulsion preparation. After
addition of LG2055, the pH of the suspension was
adjusted to 7.5 using NaHCO3, to reflect the in vivo con-
dition, in which pancreatic juice containing alkaline so-
dium (sodium bicarbonate (NaHCO3)) is secreted into
the small intestine for maintenance of a neutral pH. TESbuffer was used as a negative control, whereas a catechin
mixture derived from green tea (Wako) was used as a
positive control [20]. The prepared final suspensions
were incubated at 37°C with constant shaking (100
strokes/min) for 3 h [20]; next, the size distribution and
mean fat emulsion droplet sizes were measured using a
particle size analyzer (Microtrac ® MT3000II, Nikkiso
Co., Ltd, Tokyo, Japan). Suspensions of the five bacterial
strains (LG2055, LG1131T, LG0317, LB1002T and




Thirty healthy adults (12 men and 18 women) between
27–69 years of age were enrolled in the study. Subjects
with a frequency of defecation less than five days per
week and severe internal organ disorders, including
coronary heart disease, respiratory impairment, endo-
crinopathy, or alimentary allergy were excluded. None
of the subjects consumed special health-promoting
foods, took medications known to alter lipid metabolism,
or regularly ingested fermented milk.
Study design
The study was performed as a double-blind, randomized,
placebo-controlled clinical trial, according to the guide-
lines established in the Declaration of Helsinki. All pro-
cedures involving human subjects were approved by the
institutional review board of the Miyawaki Orthopedic
Clinic (Eniwa City, Hokkaido, Japan) prior to initiation
of the study. All subjects provided written informed
consent prior to study participation. The study was con-
ducted from January 2014 to February 2014 by a contract
research organization, New Drug Research Center, Inc.
(Minato-ku, Tokyo, Japan). The clinical trial was registered
at the University Hospital Medical Information Network
Clinical Trials (No. UMIN000015772).
Preparation of the test fermented milk
Two types of fermented milk (FM) were prepared: the ac-
tive FM containing LG2055 and the control FM lacking
LG2055. The active FM was prepared using lactic acid
bacteria starter cultures (Streptococcus thermophilus and
Lactobacillus delbrueckii subsp. bulgaricus) commonly
used for conventional yogurt production and viable
LG2055 cells. An FM mixture consisting of approximately
11% skim milk powder with a small amount of flavor, agar,
and sucralose as a non-caloric artificial sweetener was
inoculated with the yogurt starter cultures and LG2055
cells, then cultured at 40°C for 3.5–4 h. On the initial
day, the viable cell count of LG2055 was approximately
5 × 109 CFU/100 g of FM. The control FM was pre-
pared in the same manner, except that LG2055 cells
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in energy (146.4 kJ), protein (3.7 g), fat (0.1 g), carbohy-
drate (4.9 g), and sodium content (40 mg) per 100 g
and were indistinguishable in taste. The test FM prepa-
rations were kept in cold storage and delivered weekly.
Study schedule and protocol
The study length was fourteen days, comprising a seven-
day pre-observational period followed by a seven-day
FM intake period. Subjects were randomized into the
control and active FM groups. To equalize energy and
fat intakes, subjects were provided the same diets
throughout the entire study period (14 days), consisting
of different menus at each meal, each day of the study.
Energy intake was set at approximately 8368 and
9623.2 kJ per day in women and men, respectively; the
amount of fat intake was set at approximately 70 and
85 g per day (31.5 and 33.3 percent energy) in women
and men, respectively. After the seven-day pre-
observational period, both groups started consuming the
test FM for seven days. The subjects consumed FM at
100 g/d with meals (at either breakfast, lunch or dinner)
and they were asked to maintain their normal lifestyle
habits, including exercise routines. All subjects main-
tained a detailed dietary record during the entire study
period. Fecal samples were collected during the final
three days of the pre-observational (days 5–7) and FM
intake periods (days 12–14). Fecal samples were weighed
and immediately frozen for storage. Body weight, body
fat percentage, blood pressure, pulse rate, and fasting
blood parameters (triacylglycerol, total cholesterol, high
density lipoprotein cholesterol, NEFA, glucose, total
protein, aspartate aminotransferase, alanine amino-
transferase, alkaline phosphatase, and gamma-glutamyl
transpeptidase) were determined at the beginning of
the test period (day 1) and the day after the end of the
experimental period (day 15). Physician interviews were
also performed at each time point (day 1 and 15). Infor-
mation regarding subjective symptoms such as head-
ache, nausea, and abdominal pain were obtained
through a physician interview at each time point (day 1
and 15).
Measurement of fecal fat concentration
Fecal fat level was determined according to the methods
described by van de Kamer et al. [21].
Physical characteristics and blood sample analyses
Blood analyses were performed by SRL, Inc. (Shinjuku-ku,
Tokyo, Japan). The blood samples were centrifuged at
188 × g for 10 min at 4°C, and the supernatant was stored
at a temperature below −30°C until analysis. The concen-
tration of serum NEFA was measured using a biochemical
autoanalyzer JCA-BM6010 (JEOL Ltd., Tokyo, Japan). Theconcentrations of other serum parameters (triacylglycerol,
total cholesterol, high density lipoprotein cholesterol,
glucose, total protein, aspartate aminotransferase, ala-
nine aminotransferase, alkaline phosphatase, and
gamma-glutamyl transpeptidase) were measured using
a biochemical autoanalyzer AY5400 (Beckman Coulter
Inc., CA, USA).
Statistical analysis
All in vitro experiments were performed three times and
data were expressed as means with standard deviation
(SD). The Tukey-Kramer post-hoc test was used for
multiple comparisons between strains. In the human
study, the differences between the pre- and post-FM in-
take periods, and the differences between the control
and active FM groups, were evaluated using Student’s
paired t-test and Student’s unpaired t-test, respectively.
A P value < 0.05 was considered statistically significant.
Results
Effects of LG2055 on pancreatic lipase activity in vitro
We first examined the effect of LG2055 on pancreatic
lipase activity using a fat emulsion as a substrate in vitro
(Figure 1). The lipase inhibitor orlistat [13] strongly inhib-
ited lipase activity in a dose-dependent manner (0.001–
1 μg/ml); LG2055 also suppressed lipase activity in a dose-
dependent manner (1–100 μg/ml) (Figure 1A). All the
examined lactic acid bacterial species and strains signifi-
cantly suppressed lipase activity at a final concentration of
100 μg/ml compared with the control lacking bacteria.
Furthermore, LG2055 strongly suppressed lipase activity
compared with the other four strains (LG1131T, LG0317,
LB1002T, and ST19258T) (Figure 1B).
When lipase activity was measured using 4-MUO as a
substrate (Figure 2), orlistat was strongly inhibitory,
whereas LG2055 had no effect at concentrations ranging
from 1–100 μg/ml. Thus, LG2055 did not suppress lip-
ase activity using 4-MUO as a substrate. The other four
strains (LG1131T, LG0317, LB1002T, and ST19258T)
did not also suppress the lipase activity using 4-MUO
(data not shown).
Effects of LG2055 on fat emulsion droplet size in vitro
The average fat emulsion droplet size remained mostly
constant following incubation for 3 h in the absence of
LG2055 (shortly after preparation: 2.00 ± 0.41 μm, after
incubation: 2.21 ± 0.87 μm), indicating that the fat emulsion
preparation was stable for a minimum of 3 h.
The catechin mixture (1000 μg/ml) increased fat emul-
sion droplet size, as previously reported [20]. LG2055 sig-
nificantly modified droplet size distribution at the same
concentration as the catechin mixture (Figure 3A). Enlarge-
ment of the fat emulsion by LG2055 was also observed in
phase-contrast micrographs (Figure 3B).
Figure 1 Suppressive effect of lactic acid bacteria on pancreatic lipase-mediated hydrolysis of triolein in an emulsion. Substrate
suspensions (fat emulsion) were incubated with pancreatic lipase (200 U/ml) and lactic acid bacterial cells or orlistat for 30 min at 37°C. After
boiling for 2 min, released fatty acids were quantified. The suppressive activity was calculated for fatty acid production, in which the activity in
the absence of sample was represented as 100%. (A) Lactobacillus gasseri SBT2055 (LG2055) suppressed the release of fatty acids from fat
emulsion in a dose-dependent manner. (B) Comparison of the capacity of various lactic acid bacteria in suppressing fatty acid release. Each of the
five bacterial strains (LG2055, Lactobacillus gasseri SBT0317 (LG0317), Lactobacillus gasseri JCM1131T (LG1131T), Lactobacillus delbrueckii subsp.
bulgaricus JCM1002T (LB1002T), and Streptococcus thermophilus ATCC19258T (ST19258T)) was added to the lipase reaction solution at 100 μg/ml.
Values are means with standard deviations for triplicate experiments. Statistical differences between the strains were analyzed using the Tukey-Kramer
post-hoc test and significant differences (P < 0.05) are indicated using different letters.
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emulsion droplet size at concentrations ranging from 1–
100 μg/ml (Figure 4A). All five strains of lactic acid bac-
teria (100 μg/ml) significantly increased the average fat
emulsion droplet size compared with the control lacking
bacteria. In addition, LG2055 significantly increased
droplet size compared with the other strains (Figure 4B).Figure 2 Effect of Lactobacillus gasseri SBT2055 (LG2055) on
pancreatic lipase activity using 4-methylumbelliferyl oleate
(4-MUO) as substrate. Various concentrations of LG2055 and
orlistat, and 0.1 mM 4-MUO solution were mixed in the well of a
microtiter plate, and the lipase solution (50 U/ml) was added. After
incubation at 25°C for 30 min, 0.1 M sodium citrate (pH 4.2) was
added to terminate the reaction. The suppressive activity was calculated
based on the amount of 4-methylumbelliferone, in which the activity in
the absence of sample was represented as 100%. Values are means with
standard deviations for triplicate experiments.Clinical study of fecal fat excretion
The physical and biochemical blood characteristics of
the subjects were not significantly different between
groups (Table 1). No subject dropped out during the
study.
The effects of the control and active FM preparations
on physical and biochemical blood parameters are
listed in Table 2. Body weight, body mass index (BMI),
and total cholesterol levels significantly decreased simi-
larly in both groups; alanine aminotransferase (ALT)
and gamma-glutamyl transpeptidase (γ-GTP) signifi-
cantly decreased in the control FM group, and pulse
rate significantly decreased in the active FM group but
remained within the normal range. Based on daily re-
cords and physician interviews, no irregularities in daily
life or adverse events related to FM consumption were
observed during the study period, (data not shown).
There were no statistically significant differences in
wet weight of feces between groups (270.1 ± 159.0 g in
control FM group vs. 336.8 ± 116.9 g in active FM group
before FM intake; 264.9 ± 151.0 g in control FM group
vs. 304.4 ± 128.7 g in active FM group after FM intake).
After FM intake, fecal fat levels were significantly in-
creased compared with those observed before FM intake
in the active FM group, whereas no increase was observed
in the control FM group (Figure 5A). The amount of
change between pre- and post-FM intake periods in-
creased in the active FM group compared with the control
FM group, although the difference was not statistically sig-
nificant (P = 0.086).
Figure 3 Effect of Lactobacillus gasseri SBT2055 (LG2055) on fat emulsion droplet size in vitro. LG2055 or a catechin mixture was added to
the fat emulsion preparation. The suspension was incubated at 37°C with constant shaking for 3 h and the size distribution of fat emulsion was
measured using a particle size analyzer. No sample (only TES buffer) was added to the negative control and the catechin mixture was used as a
positive control. (A) Changes in emulsion droplet size distribution after incubation with 1000 μg/ml of LG2055 or catechin mixture. The
distributions are an average of three determinations. (B) Phase-contrast micrographs (scale bar: 50 μm). Black and white arrows indicate the
representative fat emulsions and LG2055 cells, respectively.
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The suppression of pancreatic lipase-mediated fat hydroly-
sis is an effective strategy for prevention of obesity and
hyperlipidemia. Pancreatic lipase inhibitors such as orlistat
are currently used clinically as pharmaceutical agents [22].
In addition, it has been reported that dietary compounds,
including chitosan [17], saponin [23], and oolong tea poly-
phenols [19], inhibit pancreatic lipase, consequently sup-
pressing dietary lipid absorption. In this study, we
observed that LG2055, a probiotic bacterium displaying
anti-obesity properties, suppressed fatty acid release from
fat emulsion in vitro (Figure 1A). Moreover, it was re-
ported that LG2055 suppresses lipid absorption in the
small intestine in vivo [4]. Taken together, these findings
suggest that suppression of pancreatic lipase-mediated fathydrolysis could represent a mechanism by which LG2055
mediates suppression of lipid absorption. Consistent with
our findings, Matsumura [24] and Zhou et al. [25] re-
ported that certain strains of Lactobacillus inhibit pan-
creatic lipase. The present study further demonstrated
that all five examined lactic acid bacterial strains,
including LG2055, had an ability to suppress lipase ac-
tivity (fatty acid release from fat emulsion) to a certain
extent (Figure 1B); however, LG2055 significantly sup-
pressed fatty acid release from fat emulsion compared with
the other strains, indicating a more potent effect. These re-
sults suggest that many strains of lactic acid bacteria likely
have the ability to suppress lipase activity. However,
LG2055 could represent a specific strain with an increased
potential for lipase suppression among lactic acid bacteria.
Figure 4 Increased effects of Lactobacillus gasseri SBT2055 (LG2055) on fat emulsion droplet size. (A) The dose-dependency of LG2055 on
the average fat emulsion droplet size. (B) Comparison among lactic acid bacteria at 100 μg/ml. Fat emulsion droplet size was measured in the
same manner as described in Figure 3. Values are means with standard deviations for triplicate experiments. Statistical differences between the
strains were analyzed using the Tukey-Kramer post-hoc test and significant differences (P < 0.05) are indicated using different letters.
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into two types: the first is suppression mediated by dir-
ect interaction between the inhibitor and enzyme,
whereas the second is associated with modification of fat
emulsion properties [26,27]. If LG2055 directly inhibits
lipase-mediated hydrolysis, its suppressive effect should
be observed when using a synthetic substrate such as 4-
MUO. We observed that orlistat inhibited lipase activity
using 4-MUO as a substrate, consistent with results
using fat emulsion. Conversely, LG2055 was not inhibi-
tory (Figure 2), indicating that LG2055 does not directly
inhibit pancreatic lipase. We also confirmed that all fourTable 1 Baseline characteristics of the study subjects
Parameters Control Active




Age (years) 40.1 ± 9.5 42.6 ± 10.8
Height (cm) 162.2 ± 6.4 163.6 ± 9.4
Body weight (kg) 57.3 ± 6.4 58.8 ± 9.6
Body fat percentage (%) 24.9 ± 6.0 25.4 ± 6.4
BMI (kg/m2) 21.8 ± 2.5 21.9 ± 2.8
Systolic blood pressure (mm Hg) 116.6 ± 13.4 120.9 ± 15.5
Diastolic blood pressure (mm Hg) 69.0 ± 9.4 77.0 ± 13.0
Pulse rate (beats/min) 67.2 ± 10.3 69.1 ± 7.3
Triacylglycerol (mg/dl) 65.1 ± 22.0 68.0 ± 30.1
Total cholesterol (mg/dl) 197.1 ± 24.7 203.7 ± 31.0
Non-esterified fatty acid (μEq/l) 398.5 ± 169.5 393.3 ± 173.7
Glucose (mg/dl) 82.4 ± 6.6 86.3 ± 5.0
Values are means ± SD.tested strains (LG1131T, LG0317, LB1002T, and
ST19258T) did not inhibit lipase activity using 4-MUO
as a substrate (data not shown). These results imply that
LG2055 acts on the fat emulsion of a substrate rather
than directly on the enzyme, leading to suppression of
lipase-mediated hydrolysis. Fat emulsion interface prop-
erties, namely droplet size and specific surface area, con-
trol lipase-mediated fat emulsion hydrolysis [14,28,29].
Therefore, we examined whether LG2055 modifies fat
emulsion properties by measuring fat emulsion droplet
size upon mixing with LG2055. LG2055 promoted fat
emulsion enlargement (Figure 3B) and dose-dependently
increased fat emulsion droplet size (Figure 4A). An in-
crease in droplet size is known to be associated with a
decrease in specific surface area, resulting in delayed
lipase-mediated hydrolysis. It has been reported that
green tea extract [15], catechin mixture [20], and green
coffee bean extract [20] increase fat emulsion droplet
size, resulting in suppression of lipid absorption. How-
ever, there are no reports evaluating the effect of lactic
acid bacteria on fat emulsion droplet size. Matsumura
[24] and Zhou et al. [25] demonstrated that certain
Lactobacillus strains inhibited pancreatic lipase activity
but did not examine the mechanisms involved. To our
knowledge, this is the first report describing an enlarge-
ment of fat emulsion by probiotics. With the exception
of LG2055, the four tested strains also promoted an in-
crease in fat emulsion droplet size (Figure 4B). However,
LG2055 significantly increased droplet size compared
with the other strains. These results are consistent with
the strong suppressive effects of LG2055 on lipase-
mediated fat hydrolysis.
It remains unclear how LG2055 increases fat emulsion
droplet size. One possibility is it that an interaction be-
tween LG2055 and bile acids (e.g. taurocholic acid)
Table 2 Initial (day 1) and final (day 15) values of physical characteristics and biochemical blood parameters (n = 15)
Parameters Control Active
day 1 day 15 day 1 day 15
Body weight (kg) 57.4 ± 6.5 55.8 ± 6.0** 58.4 ± 9.4 57.2 ± 9.2**
Body fat percentage (%) 24.2 ± 6.4 24.2 ± 5.6 25.1 ± 6.6 25.1 ± 6.9
BMI (kg/m2) 21.9 ± 2.6 21.3 ± 2.4** 21.8 ± 2.8 21.4 ± 2.9**
Systolic blood pressure (mm Hg) 117.3 ± 15.5 117.9 ± 13.6 115.9 ± 14.4 118.6 ± 15.2
Diastolic blood pressure (mm Hg) 68.7 ± 10.1 69.1 ± 10.4 71.9 ± 11.2 73.0 ± 11.6
Pulse rate (beats/min) 67.0 ± 5.9 65.9 ± 10.6 71.9 ± 9.0 67.0 ± 8.3*
Triacylglycerol (mg/dl) 67.5 ± 33.5 59.5 ± 21.3 67.2 ± 37.2 66.5 ± 32.3
Total cholesterol (mg/dl) 188.5 ± 17.9 176.1 ± 27.4* 192.7 ± 35.4 179.7 ± 28.0*
HDL cholesterol (mg/dl) 68.1 ± 10.3 68.7 ± 11.1 66.5 ± 11.8 65.6 ± 11.5
Non-esterified fatty acid (μEq/l) 331.8 ± 105.5 372.1 ± 135.1 413.1 ± 223.8 462.9 ± 169.2
Glucose (mg/dl) 85.7 ± 10.0 82.5 ± 5.8 85.3 ± 6.0 84.0 ± 6.2
Total protein (g/dl) 7.4 ± 0.3 7.4 ± 0.5 7.5 ± 0.4 7.5 ± 0.4
AST (U/l) 19.8 ± 4.6 19.1 ± 4.1 19.4 ± 4.5 19.1 ± 4.6
ALT (U/l) 20.3 ± 11.6 18.2 ± 9.4* 15.7 ± 5.6 14.3 ± 5.0
ALP (U/l) 185.4 ± 35.1 176.2 ± 35.7 185.1 ± 38.6 188.3 ± 30.4
γ-GTP (U/l) 23.2 ± 14.1 18.6 ± 9.1* 21.3 ± 10.5 18.5 ± 8.8
Abbreviations: HDL high density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, γ-GTP
gamma-glutamyl transpeptidase.
Values are means ± SD.
Significantly different from the initial values within the group; *P < 0.05, **P < 0.01.
Ogawa et al. Lipids in Health and Disease  (2015) 14:20 Page 8 of 10could contribute to the modification of fat emulsion
properties. Interestingly, it was reported that certain
Lactobacillus strains have an ability to bind and decon-
jugate taurocholic acid [30]. LG2055 also has an ability
to deconjugate taurocholic acid [16]. Bile acids haveFigure 5 Effect of intake of FM containing Lactobacillus gasseri SBT20
were collected during the final three days of the pre-observational period (be
(B) The amount of change in the fecal fat levels in the control and active
pre-observational period from those at FM intake period. Values are mea
paired Student’s t-test (A) and unpaired Student’s t-test (B). An asterisk inamphipathic properties and are critical for the emulsifica-
tion of dietary lipids in the intestine [31]. As our prelimin-
ary study demonstrated, LG2055 did not increase fat
emulsion droplet size without inclusion of taurocholic acid
prepared by the method reported by Shishikura et al. [15]55 (LG2055) on fecal fat excretion in humans. (A) Fecal samples
fore) and FM intake period (after), and fecal fat levels were determined.
FM groups. Values were calculated by subtracting fecal fat levels at
ns with standard deviations. Statistical analysis was performed using
dicates a significant difference (P < 0.05).
Ogawa et al. Lipids in Health and Disease  (2015) 14:20 Page 9 of 10(data not shown). LG2055 potentially interacts with bile
acids and destabilizes the fat emulsion, resulting in its co-
alescence. Usman et al. previously reported that LG0317,
a strain included in the present study, had a decreased
capacity to deconjugate taurocholic acid compared with
LG2055 [16]. In our study, LG0317 had a decreased effect
on fat emulsion enlargement. These findings indicate the
importance of the interaction between taurocholic acid
and lactic acid bacteria for promotion of increased fat
emulsion droplet size.
We recently reported that consumption of FM contain-
ing LG2055 decreased postprandial serum triacylglycerol
and non-esterified fatty acid (NEFA) concentrations in per-
ipheral blood after intake of oral fat-loading test meals
compared with consumption of FM without LG2055 [10].
Although triacylglycerol and NEFA concentrations in per-
ipheral blood are important biomarkers of fat absorption,
they are affected by metabolism in organs such as the liver
[32]. Thus, we evaluated fecal lipid excretion to assess
more directly the effect of LG2055 on lipid absorption in
humans. Our data show that consumption of FM contain-
ing LG2055 increased fecal fat excretion (Figure 5A/B).
Given that LG2055 suppressed pancreatic lipase-mediated
fat hydrolysis in vitro, its effects on fecal fat excretion are
likely associated with suppression of lipase-mediated fat
hydrolysis, resulting in decreased lipid absorption. In this
study, we observed that BMI and total serum cholesterol
concentration were significantly decreased, but remained
within the normal range, after FM intake in both the con-
trol and active FM groups (Table 2). We consider that this
is because energy intake by the subjects was moderately
controlled, or beneficial effects of fermented milk on lipid
metabolism [33] were taken. Consumption of LG2055 for
seven days did not significantly influence body fat percent-
age. However, constant ingestion of LG2055 over a pro-
longed period could reveal more pronounced anti-obesity
effects, as we previously demonstrated when LG2055 was
consumed daily for 12 weeks [9].Conclusions
In conclusion, our findings clearly demonstrate that
LG2055 modifies the physicochemical properties of fat
emulsion by increasing droplet size and suppressing fatty
acid release from fat emulsion. These data provide a
mechanism by which LG2055 mediates the suppression
of lipid absorption and an increase in fecal fat excretion
in humans.
Abbreviations
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